DVA

Current Thesis

The trade that ran in 2026 was a narrative reversal, not a growth story: the multi-year bear overhang ("GLP-1 drugs will collapse dialysis demand") flipped to a tailwind, and a censuses/margin inflection layered on top. DVA went from ~$115 to ~$195 (+70% YTD), printed a clean Q1 beat (adj EPS $2.87 vs $2.33 est, reported 2026-05-05), gapped +27.6%, and raised FY26 adj-EPS guidance to $14.10–$15.20. That is a real, completed re-rate. The problem for a fresh entry today: price (~[entry redacted]) is above the average analyst PT ($193.71), sits just under the all-time high ($202.69), Berkshire is trimming into strength, and there is no catalyst until the Q2 print (~early Aug). Narrative state is MATURING, not accelerating. We track it; we do not chase it here.

Bull Case

• Q1 2026 beat + raise (2026-05-05): adj EPS $2.87 vs $2.33 est (+43.5% YoY), revenue $3.42B vs $3.34B est; FY26 adj-EPS guide raised to $14.10–$15.20, operating income guide +$40M at midpoint. Volume, rate-per-treatment, and cost control all positive variances.
• GLP-1 thesis flipped (late-2025 data): GLP-1 drugs shown to cut dialysis-patient mortality ~17% → patients stay in the system longer → higher lifetime value per patient. The dominant bear case is dead.
• Treatment volume inflecting up: Q1 US dialysis treatments 7,029,525 (91,650/day), the census recovery from COVID-era excess mortality finally flowing through.
• Buyback machine + tiny float: market cap only ~$12.5B on ~64M shares; aggressive repurchase (partly buying Berkshire's stock under the ~45% standstill cap) shrinks share count → structural EPS tailwind and price support. FCF guided $1.0–1.25B.
• Sentiment shift: several houses moved Hold→Buy post-print; Zacks Rank #1; forward P/E ~12.8 is cheap for mid-teens EPS growth.

Bear Case

• Above the analysts: consensus is "Hold," avg PT $193.71 — below the $195 spot. The Street is no longer the marginal buyer. Top of range $235, but median says fairly valued.
• Berkshire trimming into strength: sold ~1.22M shares (~$183M) around Q1. Partly mechanical (standstill buyback keeps them ≤45%), but a 20-yr holder is not adding here.
• Extended: +70% YTD, ~3.6% off ATH. The fear-removal leg is spent; from here it needs operational upside, not multiple expansion.
• Defensive, low-beta (0.84): this is not a parabolic momentum vehicle. It re-rates on prints and grinds — no mania leg to ride.
• Regulatory/structural tail risk: dialysis reimbursement (Medicare rate-setting), the perennial DaVita-vs-insurer litigation, and high leverage all sit in the background.

Setup & Price Structure

• Spot: ~$195.03 (2026-06-03), +3.8% on the day. 52-wk range $101.00–$202.69. Day range $186.61–$196.45.
• Valuation: P/E 18.76, forward P/E 12.77, market cap $12.52B, beta 0.84.
• Structure read: consolidating just below ATH after the May earnings gap. Above the avg analyst PT. This is a mature uptrend digesting a gap, not a fresh breakout off support. For a momentum book that buys ACCELERATING + cluster-confirmed setups, this is neither — managed-care peers (UNH/HUM/CVS) are weak, so there is no cluster confirmation; DVA decoupled idiosyncratically.
• Where I'd actually engage: a pullback that holds the 20-week EMA (~$165) and bases, OR a clean breakout-and-retest above $203 ATH on volume. Not at $195 mid-range with no catalyst.

Catalyst Calendar (next 30 days)

• None binary in the 2026-06-04 → 2026-07-04 window. No scheduled print, no PDUFA, no known guidance event.
• Q2 2026 earnings: ~early August 2026 (est.) — the next real catalyst and the next volume/guidance check. Outside the 30-day window.
• Watch for healthcare-conference appearances / sell-side notes in June, but none is a position-mover on its own.

What Would Change Our Mind

• Upgrade to a probe/entry: pullback to and hold of the 20-week EMA (~[entry redacted]) with a higher low, or a breakout-retest over the $202.69 ATH on expanding volume — i.e., a fresh clean setup rather than mid-range chase.
• Invalidate the bull thesis: weekly close below the 20-week EMA (~$165), or a Q2 print (~Aug) showing treatments/day below Q1's 91,650 with no guidance raise = volume-recovery narrative rolled over → drop to DEAD, no re-entry until it re-bases.
• Re-accelerate to MEDIUM/HIGH: a second consecutive guidance raise at Q2 plus continued census growth would re-open a momentum entry on the next clean setup.

Correlation Notes

• Decoupled from managed care: despite the health-managed-care tag, DVA's 2026 driver is idiosyncratic (dialysis census + GLP-1 reversal), and it has outperformed a weak UNH/HUM/CVS cohort — do not treat it as a managed-care beta proxy.
• GLP-1 cross-read: ties loosely to the obesity/GLP-1 complex (LLY, NVO) but as a second-order beneficiary (longer patient survival), not a competitor — inverse of the old "GLP-1 kills dialysis" correlation.
• Berkshire overhang: BRK's ~45% standstill stake means buyback flow and any BRK disposition headlines move the tape independent of fundamentals — a single-holder concentration risk to size around.
• Low beta (0.84): weak SPY hedge value but also low drawdown amplification; sizing math should reflect that it won't move like a high-beta narrative name.